Ipsen signs research accord with Japan's Peptidream

PARIS, April 10 Wed Apr 10, 2013 1:41am EDT

Related Topics

PARIS, April 10 (Reuters) - French pharmaceutical group Ipsen has signed a research partnership with Japan's Peptidream to develop therapeutic peptides for serious diseases in Ipsen's focus areas of neurology, endocrinology, and oncology.

No financial terms were disclosed, the groups said in a joint statement on Wednesday, but the accord includes optional licensing to discover and commercialise discoveries from the partnership. (Reporting by Leila Abboud; Editing by Catherine Bremer)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.